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Abstract 
 
Background: 10-20% of patients develop long-term toxicity following radiotherapy for 
prostate cancer. Identification of common genetic variants associated with susceptibility 
to radiotoxicity might improve risk prediction and inform functional mechanistic studies.  
Methods: We conducted an individual patient data meta-analysis of six genome-wide 
association studies (n=3,871) in men with European ancestry who underwent 
radiotherapy for prostate cancer. Radiotoxicities (increased urinary frequency, 
decreased urinary stream, hematuria, rectal bleeding) were graded prospectively. 
Grouped relative risk models tested associations with ~6 million genotyped/imputed 
variants (time to first ≥grade 2 toxicity event). Variants with two-sided Pmeta<5x10-8 were 
considered statistically significant. Bayesian false discovery probability provided an 
additional measure of confidence. Statistically significant variants were evaluated in 
three Japanese cohorts (n=962). All statistical tests were two-sided. 
Results: Meta-analysis of the European ancestry cohorts identified three genomic 
signals: single nucleotide polymorphism (SNP) rs17055178 with rectal bleeding 
(Pmeta=6.2x10-10), rs10969913 with decreased urinary stream (Pmeta=2.9x10-10) and 
rs11122573 with hematuria (Pmeta=1.8x10-8). Fine scale mapping of these three regions 
identified another independent signal (rs147121532) associated with hematuria 
(Pconditional=4.7x10-6). Credible causal variants at these four signals lie in gene-regulatory 
regions, some modulating expression of nearby genes. Previously identified variants  
showed consistent associations (rs17599026 with increased urinary frequency, 
rs7720298 with decreased urinary stream, rs1801516 with overall toxicity) in new 
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cohorts. rs10969913 and rs17599026 had similar effects in the photon-treated 
Japanese cohorts.  
Conclusions: This study increases understanding of the architecture of common 
genetic variants affecting radiotoxicity, points to novel radio-pathogenic mechanisms, 
and develops risk models for testing in clinical studies. Further multi-national 
radiogenomics studies in larger cohorts are worthwhile.   
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Long-term side-effects following radiotherapy impact the health-related quality-of-
life for cancer survivors [1]. Radiation dose and irradiated volume are the most 
important factors affecting toxicity risk but are broadly similar within patient populations. 
Known modifiers of the relationship between radiation exposure and risk of radiotoxicity 
include patient age, smoking history, concurrent treatments and co-morbidities. 
However, considerable inter-individual variation in radiotoxicity remains unexplained 
after allowing for dosimetric and patient-level factors. An individual’s response to 
radiation is a heritable trait as evidenced by the similar cellular radiosensitivity of related 
individuals [2], intra-individual correlation in tissue response to therapeutic radiation [3], 
and the observation that rare mutations in some genes increase risk of radiotoxicity [4]. 
Evidence suggests common variants may explain some of the remaining inter-individual 
variation in radiotoxicity susceptibility [2, 5]. Simulation shows that the accuracy of 
models to predict radiotoxicity is improved when genetic risk variants are combined with 
clinical and dosimetric parameters [6]. 
Genetic predisposition to radiotoxicity in non-syndromic individuals is poorly 
understood. Pre-clinical studies suggest that the biologic mechanisms are complex 
involving cell death, premature senescence, inflammation, tissue remodeling with 
development of fibrosis, and vascular damage. Large genetic studies are difficult 
because it is challenging to build cohorts associated with a phenotype that takes 
months to years to develop. In addition, the radiosensitivity phenotype varies by tumor 
site and means of assessment.  
In prostate cancer patients, common radiotoxicities include increased urinary 
frequency, radiation cystitis (characterized by urinary bleeding, pain, and inflammation), 
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/advance-article-abstract/doi/10.1093/jnci/djz075/5490201 by Institute of C
ancer R
esearch user on 20 June 2019
 8 
urinary retention, and rectal bleeding [7, 8]. Radiotoxicity prevalence in prostate cancer 
survivors varies by radiation delivery modality, time of follow-up, and method of 
symptom assessment (particularly for clinician vs patient scores). A large (N=1,571) 
prospective cohort study assessing clinician-assigned toxicity using the National Cancer 
Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) reported the 
actuarial likelihood at 10 years of 15% and 9% for ≥ grade 2 urinary and rectal toxicities, 
respectively [9].  
Despite ~50% of cancer patients undergoing radiotherapy, the collection of 
radiotoxicity data is sporadic and inconsistent. Most centers do not collect data routinely 
with the detail and standardization required to conduct radiogenomic studies. There is 
also a clear potential for clinical impact, e.g., with an option for modified radiotherapy 
planning as increasingly conformal dose delivery techniques become available. The 
Radiogenomics Consortium was established to facilitate data sharing and develop 
methods for meta-analyses. Our first pooled genome wide association study (GWAS) 
performed in prostate cancer survivors demonstrated that it was possible to meta-
analyze data and identify genomic risk regions, despite the heterogeneity inherent in 
radiotherapy cohorts [11].  
As part of a long-term goal to identify sufficient variants to develop a polygenic 
risk model for radiotoxicity, we undertook a larger meta-analysis on six cohorts 
comprising 3,871 prostate cancer survivors. Secondary aims were to validate previously 
published SNPs and evaluate risk SNPs in Japanese cohorts. STROGAR guidelines 
[12] for reporting radiogenomic studies, which build on the STREGA and STROBE 
guidelines [13, 14], were followed throughout. 
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Methods 
Study Participants 
The study included individuals with prostate adenocarcinoma, treated with 
radiotherapy with curative intent, and followed prospectively for development of toxicity. 
All participants gave written informed consent, and cohorts were collected following 
standards indicated by the Declaration of Helsinki. Participants were from either 
hospital-based cohorts or clinical trials (Supplementary Methods). Supplementary 
Figure 1 summarizes the six mainly European-ancestry cohorts (RAPPER, 
RADIOGEN, GenePARE, UGhent, CCI-BT, CCI-EBRT) included in the meta-analysis 
and three Japanese cohorts (PRRG-photon, N=170; PRRG-Cion, N=538; and NTMC, 
N=254; total N=962) analyzed as a separate replication set. Individuals were excluded 
if: DNA samples/genotyping failed quality control measures; they had non-European (or 
non-Japanese) ancestry determined using a preselected panel of ancestry informative 
markers [15]; and/or data were unavailable on androgen deprivation therapy, prior 
prostatectomy, age at treatment, and total biological effective dose (BED). A previously 
published GWAS meta-analysis [11] included a subset of RAPPER (RAPPER-I), 
RADIOGEN, GenePARE (GenePARE-I), and CCI-EBRT. RAPPER-II, GenePARE-II, 
UGhent, CCI-BT, and the Japanese cohorts were not analyzed previously. 
 
Assessment of late radiotherapy toxicity 
Toxicity was assessed from six months up to 5-years after the start of 
radiotherapy, with the exception of the UGhent cohort (follow-up from 18-30 months 
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only). Different toxicity assessments were used (Supplementary Table 1). Toxicity 
grades were harmonized to the CTCAE scale (Supplementary Table 1). Assessment 
times were coarsened into discrete intervals for time-to-event analysis. Six-month 
intervals were used except for RAPPER which used 12-month intervals after the first 2 
years. Four toxicity outcomes were analyzed: increased urinary frequency, decreased 
urinary stream, hematuria, and rectal bleeding. We also tested a measure of overall 
toxicity using STAT score [21].  
 
Genotyping, Quality Control and Imputation 
 Germline DNA from whole blood was genotyped for published GWASs [5, 10, 22-
25] using Affymetrix SNP6.0 arrays (Affymetrix, Inc.; Santa Clara, CA; CCI-EBRT and 
GenePARE-I) or Illumina CytoSNP12 arrays (Illumina, Inc.; San Diego, CA; RAPPER-
1). Everything else was genotyped using Illumina OncoArray-500K BeadChips (Illumina, 
Inc.; San Diego, CA). Methods used by PRACTICAL were followed [15]. Datasets were 
processed and imputed using reference haplotypes from the1000 Genomes Project 
(see Supplementary Methods).  
 
Statistical Analysis - GWAS Meta-Analysis 
 Genetic variants were tested for associations with toxicity using a grouped 
relative risk model adjusting for androgen deprivation therapy, prior prostatectomy, age 
at treatment, and total BED. Co-variables were selected a priori to reduce 
heterogeneity. A per-allele additive genetic model was assumed. In RAPPER [26] and 
GenePARE [23, 27], where samples were genotyped in two batches using different 
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arrays, batch was included as a binary adjustment variable. Outcomes were defined as 
time from the start of radiation to onset of first occurrence of grade ≥2 toxicity (see 
Supplementary Table 1) with time coarsened into discrete intervals. Efron’s method 
was used to handle ties.  
 A fixed-effects meta-analysis using inverse variance weighting combined genetic 
variant-toxicity associations across studies. Variants were considered statistically 
significant if the two-sided meta-analysis P-value (Pmeta) was <5x10-8 and the chi-
squared test of heterogeneity p-value was >0.05. The likelihood that an association 
nominally statistically significant at a given threshold depends not only on the P-value, 
but also on the power to detect a given association. We therefore assessed the 
likelihood that our statistically significant associations represent false positives using the 
Bayes false discovery probability [28]. Supplementary Table 2 reports power analysis 
for a range of minor allele frequencies and per-allele effect sizes. All statistical tests 
were two-sided.  
 
Fine-scale mapping and credible causal variant (CCV) annotation 
Genomic regions surrounding each statistically significant association were fine-
mapped using conditional analysis (details in Supplementary Materials). CCVs were 
annotated with Variant Effect Predictor [31] to determine their effect on genes, 
transcripts, and protein sequences and overlapped with Encode enhancer-like and 
promoter-like regions [31-33]. Potential eQTLs were identified using the GTEx Portal. 
 
Statistical Analysis - Multivariable Modeling 
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Clinical and genetic variables were combined using cohort-stratified grouped 
relative risk models. Stepwise model selection was used to identify parsimonious 
multivariable models for each toxicity outcome. Confidence intervals and p-values were 
likelihood based and two-sided, with p-values ≤ 0.05 considered statistically significant. 
The proportional hazards assumption for each predictor was tested at the nominal 2-
sided 0.05 level, one at a time, by extending the model to allow separate hazard ratios 
before and after 1095 days via an interaction of each predictor with I(time > 1095 days); 
all p-values were > 0.05. Additional details are in Supplementary Methods. 
 
 
Results 
 Table 1 summarizes the characteristics of the 3,871 participants included in the 
meta-analysis. The cumulative probability of developing radiotoxicity varied by cohort 
and outcome (Figure 1 and Table 1), and agreed with prior reports [9, 37-40]. As 
expected, radiotoxicity was higher in patients receiving brachytherapy [1]. Lower 
toxicities were observed in UGhent, possibly due to differences in grading and/or 
shorter follow-up time. Bivariate Cox models provide evidence that the three urinary 
toxicities were associated with each other (e.g. HR=6.01, 95% CI=4.70 to 7.62 for 
association of decreased urinary stream with increased urinary frequency) whereas no 
urinary toxicity was associated with rectal bleeding (e.g. HR=0.96, 95% CI=0.52 to 1.60 
for association of decreased urinary stream with rectal bleeding). Meta-analysis Q-Q 
plots (Supplementary Figure 2) showed no genomic inflation, suggesting population 
structure was adequately controlled using principal components analysis to restrict the 
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study to European ancestry individuals. Three independent SNPs reached statistical 
significance with a BFDP<2% (Table 2 and Figure 2): rs17055178 with rectal bleeding 
(Pmeta=6.2x10-10), rs10969913 with decreased urinary stream (Pmeta=2.9x10-10) and 
rs11122573 with hematuria (Pmeta=1.8x10-8). Variants with MAF 1-4% and SNPs falling 
just short of our criteria, including several variants associated with a secondary endpoint 
of overall toxicity, measured using STAT score [21], are listed in Supplementary Table 
3.  
Fine-scale mapping identified CCVs (Figure 3, Supplementary Tables 4 and 5). 
A second independent signal (tagged by rs147121532, Pconditional=4.7x10-6) at 
chr1:230337180-231337180 was associated with hematuria. The first signal (tagged by 
rs11122573, Supplementary Tables 4 and 5) includes 47 CCVs (together explaining 
93% of the posterior probability of risk). These CCVs lie in active enhancer-/promoter-
like gene-regulatory regions (Supplementary Figure 3A, Supplementary Table 6). 
Their risk alleles decrease expression of AGT (encoding angiotensinogen; 
ENSG00000135744.7) and COG2 (encoding conserved oligomeric Golgi complex 
subunit 2; ENSG00000135775.9) in multiple tissues including arteries (Supplementary 
Figure 3B). The second signal with 10 CCVs (tagged by rs147121532; explaining 54% 
of the posterior probability; Figure 3, Supplementary Tables 4 and 5) has risk alleles 
that decrease expression of CAPN9 (encoding the intestinal protease, calpain-9; 
ENSG00000135773.8) and ARV1 (encoding ARE2 required for viability [ARV1] 
homolog, fatty acid homeostasis modulator; ENSG00000173409.9). The risk alleles in 
the second signal were also associated with differential expression of two non-coding 
RNAs: decreased expression of ncRNA AL512328.1 (ENSG00000244137.1), which 
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overlaps partially with AGT and CAPN9; and increased expression of ncRNA 
LOC101927604 (ENSG00000223393.1). At the chr5:156903410-157903410 region 
associated with rectal bleeding, a 15 CCV signal accounts for 98% posterior probability 
at the region (Figure 3, Supplementary Tables 4 and 5). CCVs in this region overlap 
active enhancer-like regions in gastrointestinal tissues (Supplementary Figure 3A; 
Supplementary Table 6) but none were statistically significantly associated with 
differential gene expression in GTEx (all p>0.05). At the chr9:30366808-31366808 
region, associated with decreased urinary stream, a single 15 CCV signal accounts for 
99% of the posterior probability (Figure 3, Supplementary Tables 4 and 5). None were 
statistically significantly associated with differential gene expression in the tissues 
evaluated by GTEx (all p>0.05). 
To explore biological mechanisms underpinning radiotoxicity, we computed gene 
and pathway scores from the meta-analysis results (Supplementary Tables 7 and 8). 
Nine pathways were associated (p<0.05) with multiple toxicities (Supplementary Table 
8), suggesting a common biologic mechanism. For example, the ‘ECM [extracellular 
matrix] pathway’ from the Biocarta database was associated with both increased urinary 
frequency and hematuria; ‘cytokine signaling in immune system’ from the Reactome 
database was associated with both decreased urinary stream and hematuria. 
SNPs previously associated with radiotoxicity were evaluated for replication in 
the new cohorts (Table 3). Three SNPs showed a consistent association signal 
(rs17599026 with increased urinary frequency, rs7720298 with decreased urinary 
stream, and rs1801516 with overall toxicity), thought the effect size was attenuated. 
SNPs in TANC1 [22] showed inconsistent results.  
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The new and previously published variants were evaluated in Japanese ancestry 
cohorts (Supplementary Table 9). In NTMC, the minor alleles of 4 SNPs (rs10969913, 
rs17599026, rs7720298, rs7582141) were associated with a non-statistically significant 
increased risk of toxicity, with the effect direction consistent with observations in 
Europeans. The PRRG photon cohort also showed consistent, though non-statistically 
significant, association signals for rs10969913 and rs17599026. Associations were not 
replicated in the PRRG carbon-ion cohort.  
Multivariable grouped relative risk models identified independent clinical, 
dosimetric, and/or co-morbidity factors associated with an increased hazard ratio for 
each toxicity outcome (Table 4). Importantly, SNPs remained independently associated 
with toxicity and with similar effect sizes in every model. The effect sizes for SNPs were 
similar to those of established dosimetric or patient-related risk factors. Adjustment for 
the first 7 principal components derived from analysis of European ancestry samples 
had minimal impact on model parameters. C-statistics show that while model 
performance was modest, all four models improved slightly with the addition of SNPs 
(Supplementary Table 10). 
 
 
Discussion 
Our study identified three new genomic regions associated with radiotoxicity. By 
performing the first radiogenomics fine mapping study, we identified CCVs in each 
region and demonstrated two independent signals in the region associated with 
hematuria. The CCVs in this region were associated with differential expression of local 
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/advance-article-abstract/doi/10.1093/jnci/djz075/5490201 by Institute of C
ancer R
esearch user on 20 June 2019
 16 
protein coding genes (AGT, COG2, CAPN9, ARV1) and non-coding RNAs 
(AL512328.1, LOC101927604), pointing towards possible functional mechanisms. For 
example, AGT encoding angiotensinogen is converted to the active enzyme angiotensin 
II by angiotensin converting enzyme (ACE). Prior studies suggest angiotensin signaling 
may influence radiation-induced blood vessel wall injury and interstitial fibrosis [41], and 
animal and human studies suggest that ACE inhibitors could be radio-protective [42-46]. 
The regions associated with rectal bleeding and decreased urinary stream did not 
contain CCVs associated with differential expression of nearby genes in the available 
tissue databases, and may associate with long-distance gene regulation. The rectal 
bleeding locus overlaps with active enhancer-like regions in gastrointestinal tissues, and 
further studies are needed to uncover the functional effects. 
Pathway analysis might also identify new mechanisms involved in the 
pathogenesis of radiotoxicity. For example, the top-ranking pathway associated with 
hematuria was platelet adhesion to exposed collagen. Platelet adhesion is the first step 
in the formation of a platelet plug during hemostasis in response to blood vessel wall 
injury [47]. Collagens are involved in the process and some are abundant in vascular 
epithelia [48]. Several collagen-binding proteins are expressed on platelets including 
integrins [47]. Interestingly, the integrin pathway ranked eighth for an association with 
rectal bleeding. 
Our analysis is the largest GWAS of late radiotoxicity. While heterogeneity 
across cohorts adds noise and masks statistically significant SNP-toxicity associations, 
our analysis plan addressed heterogeneity. Use of individual patient data meta-analysis 
maximizes statistical power when combining information across multiple studies [49, 
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50]. In addition, we stratified our multivariable models by study to account for 
differences in toxicity incidence and other unmeasured covariates that may differ across 
study populations. Analysis of previously identified risk SNPs provides support for the 
original discovery as the odds ratios, the best estimate of association, are in the same 
direction in the new studies. As is commonly observed, the initial effect size estimates 
for the prior GWAS-identified SNPs were upwardly biased (so-called “winner’s curse”), 
and evaluation here enabled estimation of effect sizes that more likely reflect their true 
contribution to risk of toxicity. Although unable to replicate the association at 2q24.1 
within TANC1, it is challenging due to the rarity of minor alleles within Europeans [30]. 
However, ongoing laboratory studies support a role of TANC1 in radiation response 
(personal communication from A.V.), highlighting the importance of functional studies as 
complementary to association studies.  
 The multivariable risk models demonstrate that genetic variants, treatment 
variables, and other clinical factors are independent predictors for radiotoxicity, 
supporting the suggestion that common variants can improve traditional normal tissue 
complication probability models [51, 52]. While the c-statistics for our models are 
modest, SNPs improved model performance. As cohort and sample sizes increase, 
further GWAS should uncover additional risk SNPs, and sequencing studies will 
uncover rare, possibly high-penetrance, variants. We foresee the eventual incorporation 
of polygenic scores or gene panel information into integrative models of radiotoxicity 
that also include clinical risk factors. While important to continue efforts to identify 
additional risk SNPs and rare variants, our models are ready for validation, a critical 
next step towards clinical testing. The REQUITE prospective cohort study [53] of late 
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radiotoxicity will provide an excellent opportunity to test these risk models. In addition, 
investigators are actively developing novel clinical trial approaches for testing the ability 
of risk models to personalize treatment and improve outcomes [54]. We foresee these 
models being used, e.g., to identify the small proportion of individuals with the highest 
risk for toxicity who might choose to avoid radiotherapy if watchful waiting or surgery are 
alternatives; for dose-escalation in patients with a low-risk of toxicity; and to evaluate 
how model-directed modification of planned doses to normal tissues impacts risk for 
developing toxicity. 
A strength of our study is the prospective longitudinal assessment of toxicity 
enabling use of time-to-event analysis to maximize information across multiple toxicity 
assessments. Long-term follow-up is clearly important for radiogenomic studies, and 
future work should use longitudinal analysis when possible. A second strength of our 
work is the inclusion of Japanese ancestry cohorts. Most GWAS to date focused on 
populations of European ancestry, as ethnicity inflates type I error rates and reduces 
statistical power due to population heterogeneity in allelic effects on a trait [55]. It is 
important to understand how knowledge gained from European populations transfers to 
other ethnicities. Methods are being developed to detect genetic variants associated 
with complex traits allowing for population heterogeneity [56]. Trans-ethnic studies 
suggest susceptibility loci for traits are generally shared between European and East 
Asians [57] and, because of the larger sample size, cross-population meta-analyses 
increase statistical power to detect novel loci [58]. Our cohort sizes are still too small to 
identify heterogeneity in allelic effects between ethnic groups. However, we performed 
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the first analysis exploring transferability of SNP-radiotherapy toxicity associations 
across ethnicities. 
Limitations include the lack of detailed dosimetry and comorbidity data for all 
cohorts, although our stratified analysis maximized use of data across all studies for 
multivariable models. In addition, while this is the largest GWAS of its kind to date, the 
sample size is modest compared with disease susceptibility GWAS, and was only 
powered to detect SNP-toxicity associations with relatively large effect sizes. Our study 
was too small for multi-SNP modeling, such as polygenic risk score and machine 
learning-based methods. The latter were successful for other polygenic traits and 
diseases [59] and should be re-evaluated as larger radiotoxicity cohorts become 
available. In addition, this study was not designed to identify rare variants associated 
with radiotherapy toxicity, which requires next generation sequencing of large cohorts or 
case-control studies. 
In summary, by performing the largest GWAS meta-analysis and first fine-
mapping study in radiogenomics we identified four new regions associated with 
radiotoxicity in prostate cancer. We showed the signals affect gene regulation rather 
than gene coding sequences. This study increases understanding of the architecture of 
common genetic variants affecting radiotoxicity, and demonstrates that further multi-
national radiogenomics studies in larger cohorts are worthwhile. 
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Tables 
 
Table 1. Patient characteristics by cohort for the 3,871 individuals included in the GWAS meta-analysis. 
Characteristics 
All Cohorts 
N=3,871 
RAPPER,  
N=2,010 
RADIOGEN,  
N=658 
GenePARE,  
N=492 
UGhent, 
N=311 
CCI-BT, 
N=252 
CCI-EBRT, 
N=148 
Age at treatment, median (range)* 68 (43, 86) 68 (48, 84) 72 (47, 86) 65 (43, 85) 65 (49, 81) 65 (45, 79) 68 (45, 82) 
NCCN risk group, n (%) 
Very low 
Low 
Intermediate 
High or Very high 
Not available 
 
545 (14.1) 
258 (6.7) 
2,635 (68.1) 
410 (10.6) 
23 (0.6) 
 
133 (6.6) 
82 (4.1) 
1,566 (77.9) 
229 (11.4) 
0 
 
100 (15.2) 
23 (3.5) 
447 (67.9) 
82 (12.5) 
6 (0.9) 
 
172 (35.0) 
61 (12.4) 
232 (47.2) 
27 (5.5) 
0 
 
43 (13.8)† 
21 (6.8) 
173 (55.6) 
57 (18.4) 
17 (5.5) 
 
89 (35.3) 
68 (27.0) 
95 (37.7) 
0 
0 
 
8 (5.4) 
3 (2.0) 
122 (82.4) 
15 (10.1) 
0 
Stage at diagnosis, n (%) 
T1a-c, T1x 
T2a-c, T2x 
T3a-c, T3x 
T4 
Not available 
 
1,443 (37.3) 
2,020 (52.2) 
305 (7.9) 
14 (0.4) 
89 (2.3) 
 
709 (35.3) 
1,084 (53.9) 
182 (9.1) 
0 
35 (1.7) 
 
226 (34.3) 
362 (55.0) 
54 (2.7) 
7 (1.1) 
9 (1.4) 
 
249 (50.6) 
227 (46.1) 
16 (3.3) 
0 
0 
 
101 (32.5) 
126 (40.5) 
37 (11.9) 
6 (1.9) 
41 (13.2) 
 
119 (47.2) 
132 (52.4) 
0 
0 
1 (0.4) 
 
38 (25.7) 
89 (60.1) 
16 (10.8) 
1 (0.7) 
4 (2.7) 
Gleason at diagnosis, n (%) 
≤6 
7 
≥8 
Not available 
 
1,702 (44.0) 
1,653 (42.7) 
265 (6.8) 
251 (6.5) 
 
605 (30.1) 
1,109 (55.2) 
56 (2.8) 
240 (11.9) 
 
403 (61.2) 
176 (26.8) 
70 (10.6) 
9 (1.4) 
 
310 (63.0) 
124 (25.2) 
58 (11.8) 
0 
 
142 (45.7) 
107 (34.4) 
60 (19.3) 
2 (0.6) 
 
212 (84.1) 
40 (15.9) 
0 
0 
 
30 (20.3) 
97 (65.5) 
21 (14.2) 
0 
Pre-treatment PSA, median (range) 8.9 (0, 236.0) 10.1 (0.6, 33.5) 9.7 (0.6, 236.0) 6.2 (0.6, 124.0) 6.6 (0, 150.0)‡ 6.3 (0.5, 16.0) 10.9 (1.4, 80.0) 
Radical prostatectomy, n (%)* 
Yes 
No 
 
225 (5.8) 
3,646 (94.2) 
 
0 
2,010 (100) 
 
128 (29.5) 
530 (80.5) 
 
0 
492 (100) 
 
97 (31.2) 
214 (68.8) 
 
0 
252 (100) 
 
0 
148 (100) 
Androgen deprivation therapy, n (%)* 
Yes 
No 
 
3,047 (78.7) 
824 (21.3) 
 
2,010 (100) 
0 
 
463 (70.4) 
195 (29.6) 
 
248 (50.4) 
244 (49.6) 
 
198 (63.7) 
113 (36.3) 
 
55 (21.8) 
197 (78.2) 
 
73 (49.3) 
75 (50.7) 
Type of radiotherapy, n (%) 
3D-CRT 
IMRT 
Brachytherapy 
Brachytherapy + EBRT 
 
895 (25.4) 
2,239 (57.8) 
534 (13.8) 
203 (5.2) 
 
237 (11.8) 
1,773 (88.2) 
0 
0 
 
658 (100) 
0 
0 
0 
 
0 
7 (1.4) 
282 (57.3) 
203 (41.3) 
 
0 
311 (100) 
0 
0 
 
0 
0 
252 (100) 
0 
 
0 
148 (100) 
0 
0 
Total BED§, median (range)* 123 (52, 292) 120 (107, 123) 123 (57, 127) 192 (52, 269) 136 (124, 136) 158 (80, 292) 121 (112, 134) 
Number (%) with grade 2 or worse 
toxicity 
Increased urinary frequency|| 
Decreased urinary stream** 
Hematuria‡‡ 
Rectal bleeding|||| 
 
 
436 (11.5) 
345 (9.9) 
333 (9.2) 
423 (12.5) 
 
 
219 (10.9) 
159 (7.9) 
182 (9.1) 
273 (13.6) 
 
 
60 (9.1) 
27 (4.1) 
66 (10.0) 
79 (12.0) 
 
 
113 (24.6) 
125 (27.2) 
62 (12.6) 
NA¶¶ 
 
 
8 (2.6)¶ 
NA†† 
17 (5.5)¶ 
6 (1.9)¶ 
 
 
NA# 
NA# 
NA§§ 
40 (15.9) 
 
 
15 (10.1) 
12 (8.1) 
6 (4.1) 
25 (16.9) 
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* Age at treatment, radical prostatectomy, androgen deprivation therapy, and total BED were included as covariates in the GWAS meta-analysis. Abbreviations: 
NCCN, National Comprehensive Cancer Network; PSA, prostate specific antigen; 3D-CRT, three-dimensional conformal radiotherapy; IMRT, intensity modulated 
radiotherapy; EBRT, external beam radiotherapy (either 3D-CRT or IMRT); BED, biologic effective dose. 
† NCCN risk group in the UGhent cohort was defined using pre-radiotherapy PSA rather than PSA at diagnosis. 
‡ PSA measurement is pre-radiotherapy but post-prostatectomy in patients who received prior prostatectomy. 
§ Total BED was calculated using an α/β ratio of 3 following Stock et al. 2006 IJROBP (Stock et al., 2006). 
|| Increased urinary frequency was evaluable in 3,782 participants with available baseline and follow-up data (2,010 in RAPPER, 658 in RADIOGEN, 459 in 
GenePARE, 303 in UGhent, and 148 in CCI-EBRT) 
¶ Follow-up in UGhent was from 18 months to 30 months as opposed to 6 months to 5 years in all other studies. 
# Increased urinary frequency and decreased urinary stream were not analyzed in CCI-BT because assessments were not done at regular intervals. 
** Decreased urinary stream was evaluable in 3,470 participants with available baseline and follow-up data (2,010 in RAPPER, 658 in RADIOGEN, 459 in 
GenePARE, and 148 in CCI-EBRT) 
†† Decreased urinary stream was not assessed in UGhent. 
‡‡ Hematuria was evaluable in 3,619 participants with available baseline and follow-up data (2,010 in RAPPER, 658 in RADIOGEN, 492 in GenePARE, 311 in 
UGhent, and 148 in CCI-EBRT) 
§§ Hematuria was not assessed in CCI-BT. 
|||| Rectal bleeding was evaluable in 3,379 participants with available baseline and follow-up data (2,010 in RAPPER, 658 in RADIOGEN, 311 in UGhent, 252 in 
CCI-BT, and 148 in CCI-EBRT) 
¶¶ Rectal bleeding was assigned a single grade in GenePARE using information across all follow up assessments, and so this outcome was not available for 
analysis 
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Table 2. Study-specific and overall results for new risk SNPs identified via GWAS meta-analysis* of six European ancestry cohorts. Bold values 
correspond to results from meta-analysis. 
Genetic 
variant 
Chr† 
Minor 
Allele 
MAF
‡ 
Toxicity 
outcome 
Study Info§ 
Mean minor allele 
dosage 
HR (95% CI) || Pmeta¶ Phet# 
BFDP
**, % 
Toxicity 
No 
Toxicity 
rs17055178 chr5:157,403,410 G 0.09 Time to 
first grade 
2+ rectal 
bleeding 
Meta-analysis 
RAPPER 
RADIOGEN 
GenePARE 
UGhent‡‡ 
CCI-BT 
CCI-EBRT 
- 
0.81, 0.99 
0.99 
NA†† 
0.99 
0.99 
0.98 
 
0.22 
0.33 
NA†† 
0.17 
0.25 
0.12 
 
0.13 
0.14 
NA†† 
0.14 
0.14 
0.13 
1.95 (1.58 to 2.40) 
1.78 (1.37 to 2.32) 
2.58 (1.69 to 3.95) 
NA†† 
1.38 (0.18 to 10.4) 
2.01 (0.97 to 4.20) 
1.27 (0.38 to 4.25) 
6.2x10-10 0.61 0.09 
rs10969913 chr9:30,866,808 G 0.05 Time to 
first grade 
2+ 
decreased 
urinary 
stream 
Meta-analysis 
RAPPER 
RADIOGEN 
GenePARE 
UGhent 
CCI-BT 
CCI-EBRT 
- 
0.61, 0.95 
0.95 
0.99, 0.95 
NA§§ 
NA|||| 
0.95 
 
0.04 
0.04 
0.11 
NA§§ 
NA|||| 
0.27 
 
0.02 
0.02 
0.04 
NA§§ 
NA|||| 
0.02 
3.92 (2.57 to 6.00) 
1.86 (0.76 to 4.54) 
2.03 (0.27 to 15.4) 
4.36 (2.55 to 7.46) 
NA§§ 
NA|||| 
14.3 (3.78 to 54.4) 
2.9x10-10 0.08 1.07 
rs11122573 chr1:230,837,180 T 0.06 Time to 
first grade 
2+ 
hematuria 
Meta-analysis 
RAPPER 
RADIOGEN 
GenePARE 
UGhent 
CCI-BT 
CCI-EBRT 
- 
0.99 
0.99 
0.99, 0.99 
0.99 
NA¶¶ 
1.000 
 
0.19 
0.34 
0.18 
0.47 
NA¶¶ 
0.17 
 
0.14 
0.15 
0.11 
0.14 
NA¶¶  
0.16 
1.92 (1.53 to 2.42) 
1.42 (0.99 to 2.04) 
2.40 (1.54 to 3.73) 
2.01 (1.25 to 3.22) 
3.59 (1.72 to 7.49) 
NA¶¶  
0.99 (0.13 to 7.58) 
1.8x10-8 0.14 1.96 
* Within each cohort, SNP-toxicity associations were adjusted for age at treatment, prior prostatectomy, adjuvant hormonal therapy, and total BED. Associations in 
RAPPER and GenePARE were also adjusted for genotyping batch. Abbreviations: SNP, single nucleotide polymorphism; HR, hazard ratio; CI, confidence interval; 
BFDP, Bayesian false discovery probability; MAF, minor allele frequency; NA, not analyzed. 
† Base position is according to Genome Reference Consortium Human Build 37 (hg19).  
‡Minor allele frequency for each is from PRACTICAL Oncoarray samples of European ancestry 
§Imputation info score values in RAPPER are from the cytoSNP12 array and oncoarray respectively; values in Gene-PARE are from the AffySNP6.0 array and 
oncoarray respectively; values in all other studies are from the oncoarray. 
|| Hazard ratio corresponds to the minor allele with the major allele treated as the reference group. 
¶ Two-sided Pmeta was calculated using a Wald test. 
#  Two-sided heterogeneity p-value was calculated using a Chi-square test. 
**BFPD estimated assuming a prior variance, W = 0.32^2, and prior probability of a non-null association 0.0001. 
††Rectal bleeding was assigned a single grade in GenePARE using information across all follow up assessments, and so this outcome was not available for 
analysis using time-to-event analysis. 
‡‡There were only 6 rectal bleeding events in UGhent. Exclusion of this cohort from meta-analysis had minimal impact on the results: HR 1.95, 95% CI 1.58 to 
2.41, Pmeta 6.1x10-10. 
§§ Decreased urinary stream was not assessed in UGhent. 
|||| Increased urinary frequency and decreased urinary stream were not analyzed in CCI-BT because assessments were not done at regular intervals. 
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¶¶ Hematuria was not assessed in CCI-BT.  
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Table 3. Association results for risk loci identified in prior genetic association studies.  
Genetic 
variant and 
Gene 
symbol 
Chr† 
Minor 
allele 
MAF‡ 
Toxicity 
outcome 
Results from prior publication 
Meta-analysis of new studies not included in 
prior publication 
OR 
(95% CI) 
Pmeta§ N Study, N Info* OR (95% CI) Pmeta§ 
rs17599026 
KDM3B 
chr5:137,763,798 T 0.07 Presence of 
grade 1+ 
increased 
urinary 
frequency at 2 
years after 
radiotherapy 
3.12 
(2.08-4.69) 
4.2x10-8 1,564 Meta-analysis 
RAPPER-II, N=1,255 
GenePARE-II, N=161 
UGhent, N=281 
- 
0.96 
0.96 
0.96 
1.23 (0.91 to 1.67) 
1.27 (0.90 to 1.80) 
1.10 (0.45 to 2.69) 
1.08 (0.44 to 2.64) 
0.19 
rs7720298 
DNAH5 
chr5:13,858,328 G 0.30 Presence of 
grade 1+ 
decreased urine 
stream at 2 
years after 
radiotherapy 
2.71 
(1.90-3.86) 
3.2x10-8 1,564 Meta-analysis 
RAPPER-II, N=1,255 
GenePARE-II, N=161 
- 
0.98 
0.98 
1.37 (1.01 to 1.86) 
1.27 (0.88 to 1.83) 
1.61 (0.92 to 2.82) 
0.05 
rs1801516 
ATM 
chr11:108,175,462 A 0.22 Overall toxicity||,¶ 1.21 
(0.98, 1.49) 
NR 2,697 Meta-analysis 
RAPPER-II, N=859 
GenePARE-II, N=101 
CCI-BT, N=82 
- 
NA# 
NA# 
NA# 
1.37 (1.05 to 1.78) 
1.36 (1.03 to 1.80) 
1.45 (0.63 to 3.34) 
1.18 (0.21 to 6.55) 
0.02 
rs7582141 
TANC1 
chr2:159,899,489 T 0.02 
to 
0.05†† 
Overall toxicity¶ 6.17 
(2.25, 16.9) 
4.2x10-10 1,742 Meta-analysis 
RAPPER-II, N=1,340 
GenePARE-II, N=220 
UGhent, N=285 
CCI-BT (N=114) 
CCI-EBRT, N=148 
- 
0.96 
0.96 
0.96 
0.96 
NA# 
0.98 (0.52 to 1.86) 
0.56 (0.20 to 1.59) 
0.85 (0.20 to 3.67) 
2.16 (0.71 to 6.53) 
NA** 
0.73 (0.08 to 6.38) 
0.95 
* Imputation info score values in CCI-EBRT are from the AffySNP6.0 array; values in all other studies are from the oncoarray. Abbreviations: SNP, single 
nucleotide polymorphism; OR, odds ratio; CI, confidence interval; MAF, minor allele frequency; OR, odds ratio; NA, not analyzed; NR = not reported. 
† Base position according to Genome Reference Consortium Human Build 37 (hg19). 
‡ Minor allele frequency is from PRACTICAL Oncoarray samples of European ancestry. 
§ Two-sided Pmeta was calculated using a Wald test. 
|| The previously published study included both acute and late toxicity whereas the current study only includes late toxicity. 
¶ Overall toxicity was measured using STAT score [21] based on the worst toxicity grade from 2 years to 5 years after the start of radiotherapy. Analysis is adjusted 
for pre-radiotherapy STAT score, age, androgen deprivation therapy, prostatectomy, and total BED. Analysis in RADIOGEN used genotype data from the Illumina 
Oncoarray while the previously published results used genotype data from the Affymetrix Axiom Genome-Wide CEU 1 array [22]. Additional toxicity follow-up data 
was available in the current analysis that was not available in the earlier analysis. 
# SNP was directly genotyped. 
** STAT score was not assessed in CCI-BT because it correlated perfectly with rs7582141 genotype. 
†† The minor allele frequency for rs7582141 and other SNPs in this locus vary across European sub-populations. The frequency of the C allele is 0.024 in 
RAPPER-I, 0.022 in RAPPER-II, 0.039 in RADIOGEN, 0.042 in GenePARE-I, 0.046 in GenePARE-II, 0.029 in UGhent, and 0.033 in CCI-EBRT.  
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Table 4. Multivariable models including SNPs and clinical risk factors. All models are stratified 
by study. 
Model HR (95% CI) p-value* 
Rectal Bleeding† 
rs17055178 
Rectum volume (cm3) receiving 65Gy‡ 
Rectum volume (percent) receiving 70Gy§ 
Arthritis 
Inflammatory bowel diverticular disease 
Rectal dose standard deviation§ 
Intestinal volume (percent) receiving 15Gy¶ 
Gleason score ≥ 7# 
Cardiovascular disease 
 
1.84 (1.49 to 2.24) 
1.33 (1.08 to 1.63) 
1.44 (1.18 to 1.77) 
2.06 (1.12 to 3.48) 
1.80 (1.07 to 2.83) 
1.10 (1.03 to 1.18) 
1.26 (1.03 to 1.52) 
1.25 (1.00 to 1.57) 
1.44 (1.01 to 2.02) 
 
<0.001 
0.007 
<0.001 
0.02 
0.03 
0.008 
0.03 
0.05 
0.05 
Increased Urinary Frequency** 
rs17599026 
Age at treatment > 75†† 
Diabetes 
Cardiovascular disease 
Prior pelvic surgery 
Presence of hemorrhoids 
 
1.37 (1.08 to 1.71) 
1.50 (1.16 to 1.92) 
1.53 (1.15 to 2.00) 
1.57 (1.04 to 2.31) 
1.57 (1.06 to 2.24) 
1.56 (1.02 to 2.27) 
 
0.01 
0.002 
0.005 
0.04 
0.02 
0.04 
Decreased Urinary Stream‡‡ 
rs10969913 
rs7720298 
Presence of hemorrhoids 
Prior TURP 
Bladder volume (cm3) receiving 70Gy§§ 
 
2.23 (1.36 to 3.44) 
1.25 (1.05 to 1.48) 
2.06 (1.29 to 3.13) 
1.67 (1.13 to 2.39) 
1.35 (1.09 to 1.87) 
 
0.002 
0.01 
0.004 
0.01 
0.002 
Hematuria|||| 
rs11122573 
rs75991123¶¶ 
Prior TURP 
Bladder volume (percent) receiving 74Gy## 
Receipt of EBRT*** 
Age at treatment††† 
 
1.77 (1.39 to 2.23) 
1.61 (1.22 to 2.09) 
2.33 (1.70 to 3.12) 
1.29 (1.09 to 1.51) 
1.92 (1.17 to 3.20) 
2.80 (1.21 to 5.91) 
 
<0.001 
<0.001 
<0.001 
0.003 
0.01 
0.02 
Abbreviations: HR, hazard ratio; TURP, transurethral resection of the prostate; EBRT, external beam 
radiotherapy 
* Two-sided p-value was calculated using a Wald test. 
† There were only 6 rectal bleeding events in UGhent and so this cohort was excluded from the model. 
‡ Variable was log2 transformed and includes a spline knot at 3.0cm3, the 25th percentile value. Hazard 
ratio is per doubling of volume above the 25th percentile value, with reference being values below the 25th 
percentile. 
§ Variable was log2 transformed and includes a spline knot at 1.7 percent, the 75th percentile value. 
Hazard ratio is per doubling of percent above the 75th percentile, with reference being values below the 
75th percentile. 
|| This variable is defined as the standard deviation from the mean rectal dose for the standardized rectal 
volume defined as a solid organ, for each individual patient’s dosimetry. It includes a spline knot at 
19.7Gy, the median value. Hazard ratio is per unit above the median value, with reference being values 
below the median. 
¶ Variable was log2 transformed and includes a spline knot at 3.3 percent, the 75th percentile value. 
Hazard ratio is per doubling of percent above the 75th percentile, with reference being values below the 
75th percentile. 
# Reference group is Gleason < 7. 
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** There were only 8 increased urinary frequency events in UGhent and so this cohort was excluded from 
the model. 
†† Reference group are men ≤ 75 at time of treatment. 
‡‡ There were only 12 decreased urinary stream events in CCI-EBRT and so this cohort was excluded 
from the model. 
§§ Variable was log2 transformed. Hazard ratio is per doubling of volume. 
|||| There were only 6 hematuria events in CCI-EBRT and so this cohort was excluded from the model. 
¶¶ The top SNPs in the second region associated with hematuria, rs147121532, has a minor allele 
frequency < 4% and so the next most strongly associated SNP was used in the multivariable model 
(minor allele frequency 6%). 
## Variable was log2 transformed and includes a spline knot at 1.9 cm3, the median value. Hazard ratio is 
per doubling of volume above the median value, with reference being values below the median. In 
UGhent, bladder volume (percent) receiving 75Gy was used instead of bladder volume (percent) 
receiving 74Gy. 
*** Reference group is receipt of brachytherapy alone. 
††† Age is treated as a continuous variable if above 75 years. Hazard ratio is per year of age above 75 
years, with reference being men with age less than or equal to 75. 
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Figure titles and legends 
 
Figure 1. Cumulative probability of radiotoxicity. Each graph shows the cumulative 
probability of developing grade 2 or worse radiotoxicity for each individual outcome 
within each study included in the GWAS meta-analysis. These outcomes include rectal 
bleeding (A), increased urinary frequency (B), decreased urinary stream (C), and 
hematuria (D). Numbers listed below the x-axis for each graph represent the numbers of 
patients at risk.  
 
Figure 2. Manhattan plots. The graphs show association results for rectal bleeding (A), 
increased urinary frequency (B), decreased urinary stream (C), and hematuria (D). The 
red line denotes -log p value = 5x10-8. Each point represents a SNP, with numbers on 
the x-axis denoting chromosome number.  
 
Figure 3. Regional Manhattan plots. The graphs show signals defined by fine-
mapping of the hematuria risk region chr1:230337180-231337180 (A), rectal bleeding 
risk region chr5:156903410-157903410 (B) and decreased urinary stream risk region 
chr9:30366808-31366808 (C). 
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